Affiliation:
1. Colon Cancer Project, Kyoto University Hospital‐iACT, Graduate School of Medicine Kyoto University Kyoto Japan
2. Department of Surgery, Graduate School of Medicine Kyoto University Kyoto Japan
3. Department of Personalized Cancer Medicine, Graduate School of Medicine Kyoto University Kyoto Japan
4. SCREEN Holdings Co., Ltd. Kyoto Japan
5. Medical Research Institute Kitano Hospital Osaka Japan
Abstract
AbstractExperimental techniques for patient‐derived cancer stem‐cell organoids/spheroids can be powerful diagnostic tools for personalized chemotherapy. However, establishing their cultures from gastric cancer remains challenging due to low culture efficiency and cumbersome methods. To propagate gastric cancer cells as highly proliferative stem‐cell spheroids in vitro, we initially used a similar method to that for colorectal cancer stem cells, which, unfortunately, resulted in a low success rate (25%, 18 of 71 cases). We scrutinized the protocol and found that the unsuccessful cases were largely caused by the paucity of cancer stem cells in the sampled tissues as well as insufficient culture media. To overcome these obstacles, we extensively revised our sample collection protocol and culture conditions. We then investigated the following second cohort and, consequently, achieved a significantly higher success rate (88%, 29 of 33 cases). One of the key improvements included new sampling procedures for tumor tissues from wider and deeper areas of gastric cancer specimens, which allowed securing cancer stem cells more reproducibly. Additionally, we embedded tumor epithelial pieces separately in both Matrigel and collagen type‐I as their preference to the extracellular matrix was different depending on the tumors. We also added a low concentration of Wnt ligands to the culture, which helped the growth of occasional Wnt‐responsive gastric cancer stem‐cell spheroids without allowing proliferation of the normal gastric epithelial stem cells. This newly improved spheroid culture method may facilitate further studies, including personalized drug‐sensitivity tests prior to drug therapy.
Funder
Japan Agency for Medical Research and Development
Japan Science and Technology Agency
Japan Society for the Promotion of Science
Subject
Cancer Research,Oncology,General Medicine